和黃醫藥(00013.HK)在中國啓動HMPL-295治療晚期實體瘤一期臨牀試驗
和黃醫藥(00013.HK)(HCM.US)宣佈,旗下新型口服細胞外信號調節激(酉每)(ERK)抑制劑HMPL-295,已在中國啓動治療晚期實體瘤的一期臨牀試驗。
該研究是一項多中心、開放標籤的臨牀試驗,旨在評估HMPL-295的安全性、耐受性、藥代動力學和初步療效特徵,並確定晚期惡性實體瘤患者中的最大耐受劑量以及II期臨牀研究推薦劑量(RP2D)。
和黃醫藥目前擁有HMPL-295在全球範圍內的所有權利。另外,公司亦計劃就HMPL-295的藥代動力學生物標誌物開展探索性研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.